PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.45%
Revenue growth near Drug Manufacturers - Specialty & Generic median of 5.45%. Charlie Munger might attribute this to overall industry trends.
2.54%
Gross profit growth near Drug Manufacturers - Specialty & Generic median of 2.81%. Charlie Munger would expect typical industry cost structures.
-215.47%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is -6.79%. Seth Klarman would check if external or internal factors caused the decline.
-15.44%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 4.34%. Seth Klarman would check if structural or cyclical issues are at play.
-117.73%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is -6.59%. Seth Klarman would investigate factors dragging net income down.
-120.58%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is -62.01%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-123.71%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is -71.49%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
-1.20%
Share reduction while Drug Manufacturers - Specialty & Generic median is 1.98%. Seth Klarman would see a relative advantage if others are diluting.
-1.20%
Diluted share reduction while Drug Manufacturers - Specialty & Generic median is 1.98%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
-15.34%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is -15.74%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
3.14%
Positive FCF growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch might view this as a notable advantage over peers.
No Data
No Data available this quarter, please select a different quarter.
-43.07%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is -4.88%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-27.65%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 14.05%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-3018.29%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is -100.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
67.43%
OCF/share CAGR of 67.43% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
-26.57%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is -43.96%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-5286.33%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of -53.45%. Seth Klarman might see a fundamental problem if peers maintain growth.
-248.74%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is -63.13%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-882.73%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is -68.16%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
10337.78%
Equity/share CAGR of 10337.78% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-34.81%
Negative 5Y equity/share growth while Drug Manufacturers - Specialty & Generic median is -29.54%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-58.34%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is -23.16%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.36%
Receivables growth far exceeding Drug Manufacturers - Specialty & Generic median. Jim Chanos suspects potential red flags in revenue quality.
0.65%
Inventory growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos suspects major issues in demand forecasting or potential obsolescence risk.
-1.65%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
0.34%
Positive BV/share change while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-3.77%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
-42.86%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-7.77%
SG&A decline while Drug Manufacturers - Specialty & Generic grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.